Publications by authors named "S A Tepper"
Article Synopsis
- Longer periods between headache episodes may allow the nervous system to recover better, possibly enhancing patients' quality of life and disease status.
- The study, PROMISE-2, analyzed data from over 1,000 chronic migraine patients to examine the relationship between the length of interictal periods (time between headaches) and various patient-reported health outcomes.
- Results showed that patients with interictal periods longer than 21 days reported significantly better improvements in headache impact, overall health status, and bothersome symptoms compared to those with shorter periods.
Background And Objectives: Treatment of primary bone and soft tissue sarcomas typically includes complete surgical resection with or without adjunctive modalities. Despite best efforts, for the most challenging clinical scenarios such as axial or pelvic sarcoma, five-year survival rates are reported to be between 27 and 40 %. Since quality of resection is a key determinant of oncologic outcomes, it is critical to preoperatively plan the surgical approach to improve resection accuracy, ensure sufficient surgical margins, and reduce the risk of local or metastatic recurrence.
View Article and Find Full Text PDFThe widely documented "outgroup homogeneity effect" refers to people's tendency to view members of groups to which they do not belong (outgroups) as more similar to one another than members of their own groups (ingroups). Here, we present evidence for a novel but related phenomenon: People tend to view members of different minority groups as collectively more similar to one another than members of the majority group are to one another. Across nine studies (and four studies reported in the Supplemental Materials), we demonstrate a robust "minority-groups homogeneity effect" among participants from both majority groups (Studies 1-5) and minority groups (Studies 6-8), albeit less consistently among the latter.
View Article and Find Full Text PDFArticle Synopsis
- * The ASCEND trial included adults aged 18-65 who had a history of migraines, and participants could self-administer the drug up to 12 times a month for their attacks.
- * Results showed that 14.3% of migraine attacks treated with STS101 led to mild or moderate side effects, while the drug effectively reduced pain quickly, achieving significant relief within 24 hours in many cases.
Importance: Patients with chronic migraine and medication overuse headaches (CM-MOH) represent a particularly burdened subpopulation. This trial provides first, to our knowledge, American Academy of Neurology class I evidence for a preventive therapy in CM-MOH.
Objective: To assess erenumab efficacy and safety in patients with nonopioid CM-MOH.